The Japanese pharmaceutical company Takeda has in its company strategy bet on the treatments of gastroenterology, and attend diseases rare such as hemophilia, oncology and vaccinesbecause it considers that this is where their innovation is required and with it they can grow.
In interview with MILLENNIUMHernán Porcille, general director of the firm in Mexico, explained that through 10 new highly specialized products that they have launched since 2021 and They seek to have them positioned in the market before 2030they hope to systematically increase the number of patients they serve in the country by double digits.
He stated that the nation is among his top five emerging markets, Therefore, for Takeda, the country is at the global forefront in terms of launches.
“Since the acquisition of a highly specialized company in 2019, we have focused on innovative treatments, we are thinking of launching 10 before 2030, which is part of that investment of reaffirming the commitment to Mexico,” he expressed.
These launches will be prepared in oncology, in regards to lung cancer, in the specific case of solid tumors. As well as a medicine to treat short intestine and vaccines, they are in the regulatory process to be able to distribute their dengue vaccine.
These launches will be prepared in oncology, in regards to lung cancer. | Special
Besides that In 2021 they already launched their product against hemophilia A and in gastroenterology they launched a product against Crohn’s disease and ulcerative colitis, among others.
Porcille explained that in all currently are experiencing the usual regulation timesespecially in such specific and highly specialized molecules.
In the specific case of its dengue vaccine, he highlighted that Takeda trusts and sees it as reasonable that in Within a period of 2 years, the Mexican regulatory entity accepts it for distribution.since it understands that it is preventive and this may cause it to take even longer.
In the case of its dengue vaccine, the company expects it to be authorized in two years. | Special
In 2023 Takeda opened its innovation center in Santa Fewhich is the second they have in the world and this is due to the geopolitical position of the country being close to the United States, as well as Mexican specialists and workers.
In addition to the fact that they already have an internal department which specializes in adapting these areas of innovation opportunity in the country using applications, treatments, clinical trials, among others, all specialized to the needs of the Mexican population.
He remembered that Between 2014 and 2017 they remodeled their Naucalpan plant with an investment of more than 150 million pesoswhich currently has a production volume of 114 million doses annually and mainly promotes gastroenterology products not only for Mexico.
Between 2014 and 2017 they remodeled their Naucalpan plant with an investment of more than 150 million pesos. | Special
“Currently we are the only subsidiary of the 80 that Takeda has in the world that has a complete operation (…) it is important to highlight that with the combination of our corporate offices and the manufacturing plant we employ about 450 people,” he explained and He added that each year they invest around 40 million dollars in Mexico for operational issues in the country and there are around 10 million patients who are treated.
He highlighted that Takeda, being a highly specialized portfolio, each of them has a really long patent life and even the fact of bringing innovative products is in accordance with the country’s health ecosystem.
PMA
2023-10-22 09:16:21
#Takeda #bets #growth #treating #cancer #dengue #vaccines
